RxDoctor Payments Data

Ronda Broady, DO

Family Medicine · West Chester, PANPI 1558381012

Payments from drug & device makers

$2,832in general payments, 2019–2025

Across 91 payments — averaging $31.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teladoc Health, Inc.$775
  • AstraZeneca$430
  • Lilly USA, LLC$310
  • Teva Pharmaceuticals USA, Inc.$244
  • Novo Nordisk$170
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$119
  • plus $785 from 17 others

What the payments were for

  • Speaking & faculty fees$77527%
  • Food & beverage$2,05773%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,832 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$114,400
Medicare patients
235
Services billed
1,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$59,815
FarxigaDapagliflozin Propanediol22$34,013
TrulicityDulaglutide25$30,211
JardianceEmpagliflozin13$22,365
XareltoRivaroxaban26$18,918
EliquisApixaban21$16,872
JanuviaSitagliptin Phosphate20$14,862
MounjaroTirzepatide12$12,481
Rosuvastatin Calcium164$3,615
Levemir FlexpenInsulin Detemir18$2,716
Atorvastatin Calcium211$2,646
SynthroidLevothyroxine Sodium43$2,193
Levothyroxine Sodium205$2,142
Omeprazole126$2,036
Losartan Potassium156$1,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$170$59,81552 claims
Lilly USA, LLCTrulicity, Mounjaro$310$42,69237 claims
AstraZenecaFarxiga$430$34,01322 claims
Boehringer IngelheimJardiance$34$22,36513 claims
PfizerEliquis$68$16,87221 claims
MerckJanuvia$81$14,86220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in West Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →